Cladribine (CAS 4291-63-8; molecular formula C₁₀H₁₂ClN₅O₃; relative molecular mass 285.69 g/mol) is a chlorinated deoxyadenosine analogue supplied as a pharmaceutical-grade active pharmaceutical ingredient for the manufacture of oral tablets, capsules, granules, and sterile injectable dosage forms. The molecule is a 2-chloro-2′-deoxyadenosine with a purine ring substitution that confers resistance to adenosine deaminase-mediated degradation. The API is controlled against the current European Pharmacopoeia monograph for cladribine (Ph. Eur. 2174) and the corresponding USP monograph; manufacture is conducted under ICH Q7 GMP and is intended to support marketing authorisation applications under FDA 21 CFR 314.50 and EU Directive 2001/83/EC. No universal model number applies to the molecule; manufacturer-specific grade codes are assigned for the micronized oral presentation, the granular direct-compression presentation, and the sterile non-pyrogenic injectable presentation. Release documentation includes route-specific tests for assay, related substances, residual solvents, water content, elemental impurities, microbial limits, and bacterial endotoxins.

The route-specific specification matrix is summarised in the following table. The limits shown are representative acceptance criteria derived from pharmacopoeial monographs and ICH guidelines; lot-specific certificates of analysis may apply tighter internal limits where stability or process capability data support them.

How Does Cladribine Provide a Validated Control Strategy for Low-Dose Oral Solid Dosage Manufacturing?

Particle engineering is applied because the oral dose strength is commonly 10 mg. Low-dose tablets require uniform distribution of the API; the micronized oral grade is controlled by laser diffraction per USP <429> and Ph. Eur. 2.9.31, with a target D90 of ≤20 µm for content uniformity and dissolution consistency. Direct compression of a 10 mg strength tablet on a rotary press with a paddle force feeder requires the granulated grade to maintain flowability and compressibility. Particle-size distribution, bulk density, and tapped density are reported per USP <616> and Ph. Eur. 2.9.34. The granular oral grade is typically targeted to a D50 of 80–120 µm and a bulk density of 0.45–0.55 g/mL to reduce segregation in low-dose blends. These values are batch-specific and are established during process validation rather than from a universal monograph.

Capsule filling of low-dose cladribine blends uses a dosator-type or tamping-pin encapsulation machine. The granular grade must resist over-lubrication and static charge; flow is characterised by angle of repose per USP <1174> with an acceptance range of 25–35° for automated filling. Granule manufacture by high-shear wet granulation is performed with a vertical granulator at impeller tip speeds of 4–8 m/s and a product temperature not exceeding 35 °C; subsequent drying in a fluid-bed dryer with inlet air at 55–65 °C reduces moisture to a final loss-on-drying of 1.0–2.0% for the granulate. These parameters are process-specific for formulations containing cladribine; the API itself is protected from prolonged wet massing because the chlorinated purine nucleus is susceptible to hydrolytic degradation under strongly acidic aqueous conditions. Published batch-specific data for the granular direct-compression presentation of cladribine are limited in open literature; process capability values are supplied in the active substance master file.

For the injectable route, the API is released as a sterile, non-pyrogenic material. The injectable grade is formulated into cladribine injection 1 mg/mL or into a lyophilised powder for reconstitution. The finished injectable dosage form is used under medical supervision for the treatment of hairy cell leukaemia, while oral cladribine tablets are used for relapsing forms of multiple sclerosis. The API itself is not intended for direct clinical use; it is supplied to licensed pharmaceutical manufacturers for further processing under 21 CFR 210 and 21 CFR 211 for finished drug product manufacture.

Residual Solvent, Elemental Impurity, and Particulate Matter Controls Across Route-Specific Grades

Residual solvent control follows ICH Q3C Option 1. Where the synthetic route may involve chlorinated reagents or amide solvents, class-specific limits are applied. For example, the ICH Q3C Option 1 limit for acetonitrile is 410 ppm, for dichloromethane 600 ppm, for methanol 3000 ppm, and for ethanol 5000 ppm; Class 1 solvents such as benzene (2 ppm), carbon tetrachloride (4 ppm), and 1,2-dichloroethane (5 ppm) are controlled where relevant to the route. Elemental impurities are assessed under ICH Q3D; for a parenteral route, the risk assessment must consider cadmium, lead, arsenic, and mercury with permitted daily exposure values of 2 µg/day, 5 µg/day, 15 µg/day, and 3 µg/day, respectively. Conversion of permitted daily exposure to concentration limits is based on the maximum daily dose stated in the finished product label.

For the injectable grade, bacterial endotoxin release testing is performed by the limulus amebocyte lysate method to a limit of ≤0.10 EU/mg. Sterility is demonstrated by membrane filtration per Ph. Eur. 2.6.1 or USP <71>. Particulate matter in the final injectable solution is controlled at drug product stage per USP <788>; the API contribution is minimised through controlled particle-size reduction and dedicated sterile filtration of the formulated solution where the dosage form is terminally sterilised. If terminal sterilisation is not feasible due to the heat sensitivity of cladribine, aseptic processing is used, and the sterility assurance level depends on environmental monitoring and media-fill validation under Annex 1 of the EU GMP guide.

The oral grade is not required to be sterile. Microbial enumeration limits for the oral grade are set at total aerobic microbial count ≤10² CFU/g and total combined yeasts and moulds ≤10¹ CFU/g, with absence of Escherichia coli. The oral grade is tested by the plate-count method per Ph. Eur. 2.6.12 and USP <61>, and specified microorganisms are tested per Ph. Eur. 2.6.13 and USP <62>.

When Pharmacopoeial-Grade Cladribine Replaces Research-Grade Material in Compression and Filling Trials

Replacement of research-grade cladribine with pharmacopoeial-grade material in early development changes the interpretation of formulation data. Research-grade material may lack validated particle-size control, endotoxin specifications, and full related-substance profiling; such material can exhibit different bulk density and flow behaviour in a rotary press or encapsulation machine. The resulting compression force, ejection force, and weight variation data may not be predictive of material intended for commercial manufacture. The pharmacopoeial-grade material is supplied with a certificate of analysis that includes batch-specific residual solvent, elemental impurity, and microbial data, whereas research-grade material often omits these release tests. Use of well-characterised material is therefore necessary before process qualification batches are manufactured on production-scale equipment such as a high-shear granulator, fluid-bed dryer, rotary tablet press, or isolator-based aseptic filling line.

Compared with other purine nucleoside analogues such as fludarabine and clofarabine, cladribine differs in the sugar moiety and the halogen substitution pattern. Fludarabine is a 2-fluorinated arabinosyladenine phosphate, and clofarabine is a 2-chloro-2′-fluoro-arabinosyladenine. Cladribine carries a chlorine at the 2-position and a deoxyribose sugar; the absence of the arabinose 2′-hydroxyl and the specific halogen substitution affect intracellular phosphorylation by deoxycytidine kinase and incorporation into DNA. These structural differences are reflected in the approved clinical indications and dosing schemes. The API supplier therefore verifies identity by infrared absorption and chromatographic retention time, because substitution at the 2-position and the sugar configuration cannot be distinguished by elemental analysis alone.

For the sterile injectable grade, storage and processing boundaries are set by the thermal and hydrolytic degradation pathways of cladribine. The API is supplied in sealed double polyethylene bags inside an aluminium laminate overwrap. Long-term storage is typically 2–8 °C, protected from light; where the approved application specifies a long-term storage temperature of −20 °C ± 5 °C, the manufacturer follows the registered condition. Reconstitution and formulation should avoid prolonged exposure to acidic media and temperatures above 40 °C unless stability data from forced-degradation studies support the processing step. The injectable grade is intended for manufacturing facilities with classified areas and validated aseptic processing; it is not interchangeable with oral-grade material in a dosage form because endotoxin, sterility, and particulate controls are route-specific.

The oral grade is used primarily in immediate-release tablet formulations and granules; the API is blended with lactose monohydrate, microcrystalline cellulose, and crospovidone or sodium starch glycolate. Process validation batches are sampled for blend uniformity per USP <905> and content uniformity per USP <905> or Ph. Eur. 5.1.4. Dissolution testing of finished tablets is performed under conditions specified in the drug product application; the API specification itself does not include a dissolution requirement. For capsules, the granular grade is filled after lubrication with magnesium stearate at 0.5–1.0% w/w to reduce sticking to dosator pins. For granules, the API is incorporated during wet granulation or as a dry blend before final packaging into sachets or bottles. In all oral processes, the low dose of cladribine requires segregation control through matched particle-size distributions of the API and excipients.